Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Over 66% of U.S. adults use at least one prescription drug, according to data gathered by the Health Policy Institute at ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate the necessary changes for weight loss into modern everyday life and to ...

In 2020, Trump established a temporary model through which participating Medicare prescription drug plans covered insulin products at no more than $35 a month. That model was later significantly ...

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest ...

“In 2018, when our lawsuit was filed, it could cost hundreds of dollars for Minnesotans to fill their insulin prescription. As of today, it will cost just $35. My mission as Attorney General is ...

“In 2018, when our lawsuit was filed, it could cost hundreds of dollars for Minnesotans to fill their insulin prescription," Ellison stated. "As of today, it will cost just $35." Even ...

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products for $35 per month. For the next five years ...

“In 2018, when our lawsuit was filed, it could cost hundreds of dollars for Minnesotans to fill their insulin prescription. As of today, it will cost just $35. My mission as Attorney General is ...

ST. PAUL, Minn. — Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable ...